2021 CMSC Annual Meeting

PRACTICAL CONSIDERATIONS IN RELAPSE MANAGEMENT AND DISEASE MODIFYING THERAPY (DMT) APPLICATIONS

CREDITS: CME, CNE, CPE, PA
Expiration: 30-Apr-22
Level of Information: Intermediate

Using case-based presentations, this program will assist Advanced Practice Clinicians (APC: PA & NP) in defining what constitutes an acute relapse versus a pseudo-relapse in patients with multiple sclerosis (MS) and discussing therapeutic options. We will discuss the currently available FDA-approved Disease Modifying Therapies (DMT), their pharmacologic properties and recommended monitoring. Using evidence-based medicine, we will outline an approach to starting a DMT after diagnosis and switching a DMT if necessary, due to breakthrough activity.

Presentations and Speakers

Introduction Bryan Walker, MHS, PA-C, MSCS
Acute Relapse Versus Pseudo-Relapse and Options for Treating Acute Phase. Bryan Walker, MHS, PA-C, MSCS
Overview of Currently Available Disease Modifying Therapies Jenelle Hall Montgomery, PharmD, BCACP, CPP
Decision Making in DMT’s, Initial Versus Switch Considerations Stephanie Agrella, PhD, NP, MSCN
Discussion/Q&A Panel

You can only claim credits for this On-demand Video if you have not done so for the Live Event.